Registry analysis of 36,148 relapsing-onset cases showed lower annual DMT treatment probability in late-onset versus ...

Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish ...

Most people do not use one drug, but many. SUDs often involve different substances, but the underlying problem is really one ...

Many serious conditions can present with vague or atypical symptoms, making early diagnosis challenging and highlighting the ...

Daré Bioscience, Inc. ( DARE) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT [Operator Instructions] We will take our first question from the line of Kemp Dolliver from Brookline Capital Markets.

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML ...

On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data ...

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve ...

The Delhi High Court set aside a GST demand order after finding that the taxpayer was given less than one effective working day to respond to additional queries. The Court held that such truncated ...

Most people do not use one drug, but many. SUDs often involve different substances, but the underlying problem is really one ...

The Bombay High Court held that State GST authorities could not initiate parallel proceedings and attach bank accounts when Central GST authorities were already investigating the same alleged ITC ...